The latest announcement is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA has announced the conversion of NOK 2,000,000 worth of convertible bonds into 3,333,333 new shares, increasing the company’s share capital. This move reflects Circio’s strategic financial management and could impact its market positioning by enhancing capital structure and shareholder value.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in circular RNA vector expression technology for nucleic acid medicine. Their proprietary circVec technology enhances protein expression and durability, positioning it as a potential new standard for nucleic acid and viral therapeutics. Circio is also developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations, supported by research grants and collaborative networks.
YTD Price Performance: -92.47%
Average Trading Volume: 19,930
Technical Sentiment Signal: Buy
Current Market Cap: NOK68.16M
Learn more about 0RIS stock on TipRanks’ Stock Analysis page.